Send me real-time posts from this site at my email
Motley Fool

Why Corcept Therapeutics Tanked by Almost 17% Today

What happened

Corcept Therapeutics (NASDAQ: CORT) didn't have a happy hump day. On Wednesday, the company's stock cratered by nearly 17% due to some disquieting legal news.

So what

In a regulatory filing, Corcept disclosed that it received a subpoena from the U.S. Attorney's Office (USAO) for the District of New Jersey on Nov. 15. That subpoena concerned the biotech company's only commercialized drug, Cushing's syndrome treatment Korlym.

Image source: Getty Images.

According to Corcept, the New Jersey USAO is "seeking information relating to the sale and promotion of Korlym, Corcept's relationships with and payments to healthcare professionals who can prescribe or recommend Korlym and prior authorizations and reimbursement for Korlym."

The company added that the New Jersey USAO is investigating whether it violated any criminal or civil laws when engaging in such activities. Corcept said that it is not currently considered a defendant, merely an "entity whose conduct is within the scope of the government's investigation."

Also that morning, Corcept announced that it is extending its current tender offer for shares of its common stock. That offer, which was to expire Tuesday evening at 11:59 p.m. ET, was extended to next Wednesday, Dec. 15 at the same time.

Corcept originally launched the offer on Nov. 8 for the purchase of up to 10 million shares of its common stock at a price between $20.75 and $23.75 per share. It added that these sales are contingent upon at least 3 million shares being tendered. To date, slightly over 8.28 million shares have been purchased.

The company did not provide a reason or reasons for the extension of the offer.

Now what

The words "U.S. Attorney's Office investigation" strike fear into shareholders and for good reason. Companies have been hit with stiff fines and other sanctions for breaking or bending the law. Investors are right to be hesitant about Corcept stock, and they should keep a sharp eye on how the investigation develops.

10 stocks we like better than Corcept Therapeutics
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Corcept Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of November 10, 2021

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue